Application Segment Analysis: Multiple Myeloma (MM) (Largest & Fastest-Growing Segment)

The multiple myeloma (MM) segment dominated the lenalidomide market with a revenue share of 59.81% in 2026 and is also anticipated to remain the fastest-growing application segment. Its leadership is primarily driven by the established role of lenalidomide in the long-term management of multiple myeloma across different stages of treatment, including maintenance and combination therapy. The growing emphasis on improving patient outcomes, extending disease control, and integrating immunomodulatory therapies into standard treatment protocols continues to reinforce demand. Ongoing advances in treatment strategies and increasing adoption of personalized oncology approaches are expected to further strengthen the segment's position.

Type Segment Analysis: 10mg Capsules (Largest Segment) vs 25mg Capsules (Fastest-Growing Segment)

The 10mg capsules segment accounted for the largest share of 36.61% in 2026, reflecting its widespread use in treatment regimens that require flexible dosing and long-term disease management. Healthcare providers frequently select this dosage strength to support individualized therapy plans while balancing efficacy and tolerability across different patient populations. Its versatility across various treatment settings has contributed significantly to its leading market position.

The 25mg capsules segment is expected to register the fastest growth as demand increases for dosage strengths commonly incorporated into intensive treatment protocols and combination therapies. Greater adoption of advanced therapeutic approaches and evolving clinical practices aimed at optimizing treatment effectiveness are encouraging broader utilization of higher-strength formulations. Continued refinement of oncology treatment pathways is expected to sustain growth for this segment.

End-user Segment Analysis: Hospitals (Largest Segment) vs Cancer Treatment Centers (Fastest-Growing Segment)

Holding the largest share of the lenalidomide market, the hospital segment led the market in 2026 owing to the availability of specialized oncology services, multidisciplinary care teams, and comprehensive treatment infrastructure. Hospitals remain the primary setting for diagnosis, treatment planning, medication management, and continuous patient monitoring, making them central to the delivery of complex hematological therapies. Their ability to provide integrated care supports continued market dominance.

The cancer treatment centers segment is projected to witness the fastest growth due to increasing demand for specialized oncology facilities that offer dedicated expertise and personalized treatment pathways. Growing investments in cancer care infrastructure, coupled with rising patient preference for specialized treatment environments, are enhancing the role of these centers in delivering targeted therapies. Their expanding capabilities in comprehensive cancer management continue to drive segment growth.